As a Medical Advisor for almost seven years in Big Pharma, I know what it feels like when you reach a certain level and nobody can clearly explain to you what is next in your Medical Affairs career. Interestingly, the more I tried to take on new tasks or expand my responsibilities to bring more value to the company, the less clear managers were about a corporate development path—they lacked a plan of tenure increase or succession planning.
The new Republican tax bill, which was unveiled on Thursday, proposes to get rid of tax credits that are used to develop rare disease drugs.
Under current policy, pharmaceutical and biotech companies are allowed a tax credit of up to 50% of certain research costs for rare disease drugs.
NEW YORK, Oct. 30, 2017 – The Accreditation Council for Medical Affairs (ACMA) has partnered with phactMI™, a consortium of pharmaceutical company Medical Information (MI) departments dedicated to simplifying the process by which healthcare professionals attain medical information.
“At phactMI, we understand that healthcare professionals have a wide range of medical information needs. phactMI.org is a unique portal that provides easy access for healthcare professionals to the resources of Medical Information departments of phactMI member companies.” (https://www.phactmi.org/servlet/servlet.FileDownload?file=00Po000000TYK4K)
NEW YORK, Oct. 10, 2017 — The Accreditation Council for Medical Affairs (ACMA), a leading organization within medical affairs in the pharmaceutical industry has appointed Dr. Sotirios G. Stergiopoulos as President of the ACMA Board of Governors.
Dr. Stergiopoulos is currently the Senior Vice President & Head of Global Medical Affairs at Ipsen Bioscience. He has extensive experience in directing medical affairs worldwide strategies and plans and a solid expertise in Oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumor indications. His past experience includes Vice President, Head of Global Medical Affairs Oncology at Baxalta (now Shire, Cambridge, MA), Executive Medical Director Oncology US Medical Affairs at Celgene Corporation (Summit, NJ), Senior Global Brand Medical Director Oncology at Novartis Pharmaceuticals (East Hanover, NJ) and Director Medical Affairs Oncology at Bayer Healthcare (Montville, NJ).
“Sotirios brings an extensive background in medical affairs to the ACMA and is a well-respected thought leader within the pharmaceutical industry,” said Dr. William A. Soliman, Executive Chair of the ACMA. “We are excited to have him as president of our board.”
“I am honored that the ACMA has appointed me as President of the Board of Governors. The ACMA has an important mission which will help improve the quality of pharmaceutical industry professionals worldwide and therefore improve patient care” said Dr. Stergiopoulos.
NEW YORK, Oct. 5, 2017 – Executive Chair of the ACMA, William Soliman, PhD, MPhil, MA, BCMAS, will be presenting as a panelist at the 5th annual, Careers in Science Communication and Management Conference at the Icahn School of Medicine at Mount Sinai in New York, New York.
Dr. Soliman will join other industry experts working in pharmaceuticals, publications, and non-profits to discuss career opportunities in the field of Medical Affairs.
“I am greatly looking forward to sharing both my personal and professional insights with the students at Mount Sinai,” Dr. Soliman expressed. “While there are many opportunities for PhD, MD, and PharmD professionals in the pharmaceutical industry, the job market is extremely competitive. These young professionals are the future and I am honored to be given the opportunity to help them navigate the field of medical affairs.”
For more information about the event, please visit http://icahn.mssm.edu/about/sinainnovations
NEW YORK, Sept. 20, 2017 – Dr. William Soliman will be representing the Accreditation Council for Medical Affairs (ACMA) at the Medical Affairs Strategic Summit (MASS) West in San Diego, California on September 25-27, 2017.
Dr. Soliman will be speaking to several industry members regarding the future of Medical Affairs.
“Over the past 10 years, Medical Affairs has grown at an astounding rate… by nearly 300%” Dr. Soliman expressed. “Given this growth, it is vital for us, as Medical Affairs professionals, to prepare ourselves for the future.”
The ACMA accredits the Board Certification Program in Medical Affairs or the BCMAS program. It is the only accredited program medical affairs program in the world.
The medical affairs function has two primary goals : (1) educate and disseminate medical information and (2) generate new data. Medical affairs is involved in a variety of important decisions related to pharmacovigilance, health econ omics research and designing clinical trials among other functions . The value that medical affairs contributes within the medical community can be seen on a daily basis. Indeed, health care providers (HCPs) are increasingly relying more on the “medical arm” of the industry for ed ucation vs. the sales team. To fully understand the background and reason for this, it is important to provide a brief review of som e historic industry milestones over the last decade.
Rutgers iJOBS is excited to have biomedical graduate students and postdoctoral fellows completing the Board Certification in Medical Affairs Specialist program. iJOBS is funded by the NIH Broadening Experiences in Scientific Training (BEST) initiative with the goal of exposing PhD students and postdocs to careers outside of academia so they can make informed decisions about their futures. Many of our iJOBS trainees have expressed interest in a career in Medical Affairs within the pharmaceutical industry and the BCMAS program is a systematic mechanism for training scientific and clinical professionals in the topics related to this field.
A few weeks ago, the Food and Drug Administration (FDA), released a report establishing a final rule amending regulatory definitions of what is considered “intended use” for drugs which had originally required drug companies to include labeling for unapproved uses the drug company knew about. The FDA revised this in January stating that if a drug company has plans to promote a drug off-label based on the “totality of the evidence” then similar labeling was required.